Rybelsus vs Ozempic Tablets: Same Drug, Different Numbers, and How to Switch Safely

Rybelsus and Ozempic tablets are the same medicine. Both are once-daily semaglutide tablets from Novo Nordisk for adults with type 2 diabetes, and both contain the same active drug as the weekly Ozempic injection. What differs is the number printed on the tablet. The newer tablet is absorbed better, so 4 mg of it does what 7 mg of the original did, and 9 mg does what 14 mg did.

That sounds like a small labelling detail. It is a recognised source of dosing mistakes with oral semaglutide, regulators in the UK and Europe have issued warnings about it, and the name on the box now depends on the country you are in. This guide sets out what changed, how the strengths pair up, what the US label says about switching, and what the trials found, with every number taken from the current prescribing information.

The short answer

Rybelsus 3 mg, 7 mg and 14 mg are the original tablets. Ozempic tablets 1.5 mg, 4 mg and 9 mg are a newer formulation of the same drug. The pairs are 3 mg with 1.5 mg (starting dose only), 7 mg with 4 mg, and 14 mg with 9 mg. The US label says the two products are not substitutable milligram for milligram, that you should not switch during the first 30 days, and that when you do switch you start the new tablet the day after your last dose of the old one.

Question	Answer
Active ingredient	Semaglutide, the same molecule as Ozempic and Wegovy injections
Maker	Novo Nordisk
Original tablets	Rybelsus 3 mg, 7 mg, 14 mg (oval)
Newer tablets	Ozempic tablets 1.5 mg, 4 mg, 9 mg in the US (round); sold as Rybelsus 1.5 mg, 4 mg, 9 mg in the EU, UK and Canada
Uses in the US label	Blood sugar control in adults with type 2 diabetes; lowering the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk
How often	One tablet once a day, on an empty stomach
Prescription	Prescription only in the US, UK, Canada and Australia

What changed in 2026

The FDA approved the newer formulation at 1.5 mg, 4 mg and 9 mg in December 2024, at first under the Rybelsus name. On 30 January 2026 it approved Ozempic as the brand name for those three strengths, and Novo Nordisk announced the change on 4 February 2026. The company launched Ozempic tablets across the US on 4 May 2026 and is phasing out the original Rybelsus tablets there. The current US label still covers both products, which is why it carries a switching table.

Two other approvals sit around this one. In October 2025 the FDA added cardiovascular risk reduction to the oral semaglutide label, based on the SOUL trial covered below. In December 2025 it approved Wegovy tablets for weight management, which are a different product with a different dose range.

Same molecule, better absorption

Semaglutide is a peptide, and stomach acid and enzymes destroy most peptides before they can be absorbed. Both tablets contain an absorption enhancer called SNAC (salcaprozate sodium), which protects a small amount of semaglutide in the stomach and helps it cross the stomach lining. Absorption happens mainly in the stomach, and the peak level in the blood comes about an hour after the dose.

The fraction that gets through is tiny. The label puts the absolute bioavailability of Rybelsus at about 0.4% to 1%, and of Ozempic tablets at about 1% to 2%. Because the newer tablet delivers roughly twice as much of each milligram, it needs fewer milligrams to reach the same level in the blood. In a study in healthy volunteers, steady-state exposure on 1.5 mg, 4 mg and 9 mg Ozempic tablets showed no clinically significant difference from 3 mg, 7 mg and 14 mg Rybelsus.

How the strengths pair up

Stage	Rybelsus	Ozempic tablets	What the label says
Days 1 to 30 (starting dose)	3 mg once daily	1.5 mg once daily	Not effective for blood sugar; it lets the stomach adjust
Days 31 to 60	7 mg once daily	4 mg once daily	First treatment dose
Day 61 onward, if enough	7 mg once daily	4 mg once daily	Stay on this dose
Day 61 onward, if more control is needed	14 mg once daily	9 mg once daily	Highest US dose

Read the table as pairs, not as six separate numbers. A person moving from 14 mg to 9 mg has not had their dose cut. A person moving from 4 mg to 7 mg has not had a small increase; they have been put on a different product, and their exposure has not meaningfully changed.

The label's switching rules between the two tablets

Section 2.3 of the US prescribing information sets out three rules:

• Do not switch between Rybelsus and Ozempic tablets during the first 30 days of treatment.
• After those 30 days, a switch is allowed between the paired strengths: 7 mg to 4 mg, or 14 mg to 9 mg, and the reverse.
• Start the new tablet the day after the last dose of the old one. There is no gap and no overlap.

The label does not explain the no-gap rule, but the pharmacology fits it: semaglutide has a half-life of about one week and stays in the blood for about five weeks after the last tablet, so a pause of a few days would not wash it out.

Switching from Ozempic injection to tablets

The US label covers one case only: people on the 0.5 mg weekly injection. One week after the last 0.5 mg injection, they can start Rybelsus 7 mg or 14 mg, or Ozempic tablets 4 mg or 9 mg, once a day. There is no starting phase on this route.

The US label gives no conversion for people on the 1 mg or 2 mg injection. In the EU the Rybelsus product information goes further: a 1 mg weekly injection can move to 9 mg or 25 mg daily, and a 2 mg weekly injection to 25 mg or 50 mg daily. No 25 mg or 50 mg semaglutide tablet is approved for type 2 diabetes in the US, so this is not a route a US prescriber can follow with US diabetes products. The EU product information also warns that the effect of switching between oral and injected semaglutide cannot easily be predicted, because absorption from the tablets varies more from person to person. Anyone on a higher injection dose who wants to switch needs that decision made by their prescriber.

What "Rybelsus" means depends on the country

This is where most of the confusion now comes from. The same brand name covers different formulations in different places:

Where	What the oral semaglutide tablet is called	Strengths
United States	Ozempic tablets (new formulation); original Rybelsus being phased out	1.5, 4, 9 mg (Rybelsus 3, 7, 14 mg during the changeover)
European Union	Rybelsus, with the old tablets being replaced by the new formulation	1.5, 4, 9 mg, plus 25 and 50 mg
United Kingdom	Rybelsus, switched to the new formulation; the MHRA expected the old tablets to be available until about 31 January 2026	1.5, 4, 9 mg replacing 3, 7, 14 mg
Canada	Rybelsus, with the new formulation launched on 9 June 2026; existing patients switch with their prescriber	1.5, 4, 9 mg replacing 3, 7, 14 mg
India	Rybelsus from Novo Nordisk India; the packs we stock are the original formulation	3, 7, 14 mg

Regulators warned about this directly. The UK MHRA's Drug Safety Update of 17 December 2025 said overdose can happen if more than one tablet a day of the new formulation is prescribed to match an old strength, and that imported stock of the original formulation may stay in supply chains after the UK changeover. Belgium's regulator noted that the two formulations would sit on the market together for a while from 1 April 2026 and flagged the same risk. The rule in every country is one tablet a day.

A worked example of the commonest mix-up

Take a man in the UK who has been stable on Rybelsus 14 mg for two years. His pharmacy now hands him Rybelsus 9 mg. The name on the box is the same, the number is lower, and he assumes his dose has been reduced by a third. If he "tops up" by taking a 9 mg tablet and an old 14 mg tablet he still has on the same morning, he doubles his exposure, and nausea and vomiting are the likely result.

The same mistake runs the other way. Someone in the US who switches from Ozempic tablets 9 mg to an imported Rybelsus 14 mg tablet has not increased their dose. Their exposure is the same. The rule is simple: check the brand name and strength on every pack. For diabetes tablets, 1.5, 4 or 9 mg means the newer formulation and 3, 7 or 14 mg means the original. Do not go by tablet shape or strength alone: Wegovy tablets for weight loss also come in 1.5, 4 and 9 mg, and the EU's newer 25 mg and 50 mg Rybelsus tablets are oval.

How well the tablets lower blood sugar

The clinical trials were run with Rybelsus 7 mg and 14 mg, and the US label applies those results to Ozempic tablets 4 mg and 9 mg because their exposure showed no clinically significant difference. In Trial 1, 703 adults with type 2 diabetes not controlled by diet and exercise took semaglutide tablets alone or placebo for 26 weeks.

Week 26 result	Placebo	7 mg (pairs with 4 mg)	14 mg (pairs with 9 mg)
HbA1c at start	7.9%	8.0%	8.0%
Change in HbA1c	-0.3	-1.2	-1.4
Difference from placebo		-0.9	-1.1
Reached HbA1c below 7%	31%	69%	77%
Change in fasting glucose (mg/dL)	-3	-28	-33
Change in body weight	-1.4 kg	-2.3 kg	-3.7 kg

The step from 7 mg to 14 mg added about 0.2 points of HbA1c and about 1.4 kg of weight loss on average. That is why the label keeps people on 7 mg (or 4 mg) if their blood sugar is controlled, and moves up only when more control is needed.

Side effects by dose

Stomach and bowel effects are the main problem with semaglutide tablets, and they rise with dose. In the pooled placebo-controlled trials, 21% of people on placebo reported a gastrointestinal adverse reaction, against 32% on 7 mg and 41% on 14 mg. Severe reactions were uncommon: 0.3%, 0.6% and 2.0%. Most nausea, vomiting and diarrhea happened while the dose was being increased.

Adverse reaction	Placebo (n=362)	7 mg (n=356)	14 mg (n=356)
Nausea	6%	11%	20%
Abdominal pain	4%	10%	11%
Diarrhea	4%	9%	10%
Decreased appetite	1%	6%	9%
Vomiting	3%	6%	8%
Constipation	2%	6%	5%

Stopping because of these effects followed the same pattern: 1% on placebo, 4% on 7 mg and 8% on 14 mg. This is the practical reason the 30-day starting dose exists, and why an accidental double dose during a formulation switch tends to show up as nausea within days. Our guide to semaglutide side effects by dose covers the injection data as well.

Heart outcomes: what the SOUL trial found

Trial 7, known as SOUL, randomised 9,650 adults aged 50 or over with type 2 diabetes and heart disease, chronic kidney disease or both to semaglutide tablets 14 mg or placebo on top of their usual care. Median follow-up was a little over four years.

Outcome	Placebo (n=4,825)	Semaglutide 14 mg (n=4,825)	Hazard ratio (95% CI)
MACE (primary endpoint)	668 (13.8%)	579 (12.0%)	0.86 (0.77 to 0.96)
Cardiovascular death	320 (6.6%)	301 (6.2%)	0.93 (0.80 to 1.09)
Non-fatal heart attack	253 (5.2%)	191 (4.0%)	0.74 (0.61 to 0.89)
Non-fatal stroke	161 (3.3%)	144 (3.0%)	0.88 (0.70 to 1.11)

Only the combined MACE endpoint was formally tested; the label lists the three parts for context. The largest difference among them was in non-fatal heart attacks (4.0% against 5.2%), but the parts were not tested on their own. More people stopped the study drug because of an adverse event on semaglutide (15.5%) than on placebo (11.6%). An earlier and shorter trial, PIONEER 6 (Trial 8), was designed to show the tablets were not worse than placebo for cardiovascular risk and met that test (hazard ratio 0.79, 95% CI 0.57 to 1.11; events in 3.8% against 4.8%).

Tablet or weekly injection?

Oral and injected semaglutide are the same drug, so for most people the choice is about routine and tolerance. One real difference is breastfeeding: the tablets contain SNAC, which passes into breast milk, and their label says breastfeeding is not recommended during treatment. The tablet suits people who do not want injections and can keep to a strict morning routine every day. The weekly injection suits people who find the empty-stomach rule hard, who take several other morning medicines, or who need the higher doses the injection allows (1 mg and 2 mg weekly in the US). The injection also has its own kidney outcome indication in the US label, which the tablets do not.

Never use a tablet and an injection at the same time. The Wegovy label says combining semaglutide products with each other or with any other GLP-1 receptor agonist is not recommended, and the same logic applies to Ozempic and Rybelsus.

The morning routine the tablet needs

Because so little semaglutide is absorbed, small changes in how the tablet is taken make a large difference. The label rules are the same for both products:

• Take it first thing in the morning on an empty stomach.
• Swallow it whole with no more than 4 ounces (about 120 mL) of plain water. No coffee, tea, juice or other drinks.
• Do not split, crush, chew or dissolve it.
• Wait at least 30 minutes before eating, drinking anything else or taking other tablets.
• Take only one tablet a day. If you miss a dose, skip it and take the next one the following day.
• Keep the tablets in their original pack to protect them from moisture, at 20 to 25°C (68 to 77°F).

The label explains why: in healthy volunteers, absorption was higher with a small sip of water than with a full glass, and higher the longer people waited before eating. Our Rybelsus dosage guide goes through each rule in more detail.

Who should not take either tablet

Both tablets carry a boxed warning about thyroid C-cell tumours, which semaglutide caused in rodents. It is not known whether this happens in people. Both are contraindicated in:

• anyone with a personal or family history of medullary thyroid carcinoma;
• anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);
• anyone who has had a serious allergic reaction to semaglutide or to any ingredient in the tablets, including anaphylaxis or angioedema.

A lump in the neck, trouble swallowing, shortness of breath or persistent hoarseness should be checked by a doctor.

Warnings worth knowing

• Severe stomach and bowel reactions. Severe reactions were reported in 2% of people on 14 mg against 0.3% on placebo. The tablets are not recommended for people with severe gastroparesis (very slow stomach emptying).
• Allergic reactions. Stop the tablets and get help straight away for swelling of the face, lips or throat, trouble breathing or a severe rash. The label advises caution in anyone who has had anaphylaxis or angioedema with another GLP-1 medicine.
• Pancreatitis. Stop the tablets and get medical help for severe, persistent abdominal pain, with or without vomiting.
• Low blood sugar. The risk rises when semaglutide is combined with a sulfonylurea or insulin; the doses of those medicines may need lowering.
• Diabetic eye disease. Rapid improvement in blood sugar can temporarily worsen diabetic retinopathy. People with a history of retinopathy should be monitored.
• Kidney injury from dehydration. Severe vomiting or diarrhea can lead to acute kidney injury. Keep fluids up and seek help if you cannot.
• Gallbladder disease. Gallstones and gallbladder inflammation were reported; seek care for pain under the right ribs, fever or yellowing skin.
• Sudden loss of vision. In June 2025 the EMA's safety committee concluded that non-arteritic anterior ischaemic optic neuropathy (NAION), a type of optic nerve damage, is a very rare side effect of semaglutide. Sudden vision loss in one eye needs urgent medical attention.
• Surgery and sedation. Semaglutide slows stomach emptying, and there are rare reports of food being inhaled under anaesthesia. Tell the surgical team you take it.

Medicines that interact

Semaglutide slows the stomach, so it can change how other tablets are absorbed. In a study, taking levothyroxine with semaglutide tablets raised total thyroxine exposure by 33%. The label advises extra monitoring for any oral medicine with a narrow safety margin or one that needs blood tests, such as levothyroxine. No clinically important changes were seen with lisinopril, warfarin, metformin, digoxin, the contraceptive pill (ethinyl estradiol and levonorgestrel), furosemide or rosuvastatin, and omeprazole did not change semaglutide levels.

Pregnancy, breastfeeding, kidneys and liver

In animal studies semaglutide harmed the developing fetus, and the US label says the tablets should be used in pregnancy only if the potential benefit justifies the potential risk. Women planning a pregnancy should stop them at least two months beforehand, because the drug takes that long to clear. Breastfeeding is not recommended while taking the tablets, because SNAC and its breakdown products pass into breast milk; injected semaglutide does not contain SNAC. No dose change is needed for kidney or liver impairment: semaglutide levels were not meaningfully different in people with mild, moderate or severe kidney disease, including end-stage kidney disease, or with any degree of liver impairment.

What a month costs in the US in 2026

The Medicaid NADAC survey records what US pharmacies pay for medicines. As of 30 September 2026, the tablets and the injection cost pharmacies almost exactly the same per month:

Product	US pharmacy cost (NADAC)	About a month
Rybelsus 3, 7 or 14 mg tablet	About $33.19 per tablet	About $996 for 30 tablets
Ozempic tablets 1.5, 4 or 9 mg	About $33.13 to $33.18 per tablet	About $994 to $995 for 30 tablets
Ozempic injection pen (3 mL)	About $332 per mL	About $996 per pen, four weekly doses

Every strength costs the same, so moving from 7 mg to 14 mg does not change the price. What patients actually pay depends on insurance, discount programmes and the pharmacy's markup, so anyone with US coverage should check that first.

Where Wegovy tablets fit

Wegovy tablets are oral semaglutide for weight management, not for diabetes. The FDA approved them in December 2025 at 1.5 mg, 4 mg, 9 mg and 25 mg, with 25 mg once daily as the maintenance dose. They are labelled for long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and for lowering cardiovascular risk in adults with heart disease and obesity or overweight. A Wegovy 9 mg tablet and an Ozempic 9 mg tablet should never be taken together, and neither should be used to stand in for the other without a prescriber's decision. Our generic semaglutide guide covers the injectable weight-loss products.

Buying Rybelsus from SafeRxPills

We stock Rybelsus 3 mg, Rybelsus 7 mg and Rybelsus 14 mg from Novo Nordisk India. These are the original formulation, so the US pairings above apply: our 7 mg matches Ozempic tablets 4 mg and our 14 mg matches 9 mg. As of 2 October 2026 the per-tablet price runs from $6.50 to $7.00 for 3 mg, $8.77 to $10.50 for 7 mg and $10.33 to $12.00 for 14 mg, depending on pack size, before shipping ($25 under $149, free from $149).

Rybelsus is a prescription medicine in the US, UK, Canada and Australia. Type 2 diabetes needs regular HbA1c checks and a prescriber who knows every medicine you take, especially if you also use insulin or a sulfonylurea. If you are moving between formulations, tell your prescriber and pharmacist which one you have, and check the strength on every new pack. For how oral semaglutide compares with other tablet options, see our comparisons of Jardiance and Farxiga and Januvia and Tradjenta, or the type 2 diabetes treatment page.

Sources

• RYBELSUS and OZEMPIC (semaglutide) tablets, US prescribing information (Novo Nordisk), revised January 2026, sections 1, 2, 4, 5, 6.1, 7, 8, 12.3, 14 and 16. DailyMed
• OZEMPIC (semaglutide) injection, US prescribing information. DailyMed
• WEGOVY (semaglutide) injection and tablets, US prescribing information, June 2026, sections 1 and 2. DailyMed
• Novo Nordisk. Novo Nordisk introduces Ozempic pill; available in the US Q2 2026. 4 February 2026. Drugs.com
• Drugs.com. Rybelsus FDA approval history. Drugs.com
• Drugs.com. Ozempic FDA approval history. Drugs.com
• Pharmacy Times. From Rybelsus to the Ozempic pill: what pharmacists need to know. Pharmacy Times
• European Medicines Agency. Rybelsus: risk of medication error due to new tablet formulation (DHPC). EMA
• European Medicines Agency. Rybelsus EPAR product information, section 4.2. EMA
• MHRA. Rybelsus (semaglutide tablets): transition to new formulation and risk of medication error. Drug Safety Update volume 19, issue 5, 17 December 2025. GOV.UK
• European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines, June 2025. EMA
• Novo Nordisk Canada. Novo Nordisk introduces updated Rybelsus tablet formulation in Canada, 9 June 2026. Newswire
• Federal Agency for Medicines and Health Products (Belgium). Rybelsus: reminder of the risk of medication errors due to the introduction of a new formulation. FAMHP
• Centers for Medicare and Medicaid Services. National Average Drug Acquisition Cost (NADAC), 2026 file, as of 30 September 2026. data.medicaid.gov

This guide is for information only and is not medical advice. Semaglutide is a prescription medicine; do not change formulation, dose or schedule without your prescriber.